Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 6atezolizumab 5Cisplatin 5Ipilimumab 4Carboplatin 4Etoposide 3pembrolizumab 2gallium Ga 68 dotatate 2dostarlimab 2Temozolomide 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Magnetic Resonance Imaging 2Irinotecan 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Disulfides 2zimberelimab 1tivozanib 1repotrectinib 1niraparib 1lutetium Lu 177 dotatate 1lenvatinib 1iadademstat 1durvalumab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × BAY 1895344 × 1 year × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡